3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Squamous Cell Carcinoma of Head and Neck
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Pharyngeal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Erythrocytosis, Familial, 4
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
6
Cisplatin
6
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Radiotherapy
3
Radiation
3
Nivolumab
3
Fluorouracil
3
Biopsy
3
Surveys and Questionnaires
2
Radiosurgery
2
Paclitaxel
2
Chemoradiotherapy
2
Cetuximab
2
2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a
2
zimberelimab
1
toripalimab
1
temsirolimus
1
peposertib
1
nabiximols
1
motexafin gadolinium
1
mogamulizumab
1
ipatasertib
1
dl1520
1
camrelizumab
1
brodalumab
1
belinostat
1
apatinib
1
advexin
1
Valproic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Mouth Neoplasms
×
zimberelimab
×
Clear all
NCT04892875
2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1
Withdrawn